At present, there are only two Phase I/II trials evaluating the efficacy of gene therapy in patients harbouring mutations in FKRP (causing both DGP and LGMDR9), although these are exclusively recruiting individuals with a LGMD phenotype (NCT05224505 and NCT05230459). The gene discussed is FKRP; the disease is limb-girdle muscular dystrophy.